Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
30.77
+1.52 (5.20%)
At close: Jun 26, 2026, 4:00 PM EDT
30.00
-0.77 (-2.50%)
After-hours: Jun 26, 2026, 6:54 PM EDT
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for Ultragenyx Pharmaceutical stock have an average target of 53.17, with a low estimate of 25 and a high estimate of 96. The average target predicts an increase of 72.80% from the current stock price of 30.77.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ultragenyx Pharmaceutical stock from 19 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 14 | 13 | 13 | 12 | 12 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 1 | 1 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 20 | 20 | 20 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $79 | Buy | Maintains | $79 | +156.74% | Jun 10, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $74 → $72 | Buy | Maintains | $74 → $72 | +133.99% | May 23, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $84 → $96 | Buy | Reiterates | $84 → $96 | +211.99% | May 21, 2026 |
| Evercore ISI | Evercore ISI | Buy Maintains $34 → $33 | Buy | Maintains | $34 → $33 | +7.25% | May 11, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $50 | Buy | Reiterates | $50 | +62.50% | May 11, 2026 |
Financial Forecast
Revenue This Year
741.43M
from 673.00M
Increased by 10.17%
Revenue Next Year
983.59M
from 741.43M
Increased by 32.66%
EPS This Year
-4.24
from -5.83
EPS Next Year
0.97
from -4.24
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 769.1M | 1.6B | |
| Avg | 741.4M | 983.6M | |
| Low | 714.1M | 818.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 14.3% | 120.9% | |
| Avg | 10.2% | 32.7% | |
| Low | 6.1% | 10.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -4.12 | 5.61 | |
| Avg | -4.24 | 0.97 | |
| Low | -4.41 | -1.60 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.